董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sunil Agarwal | 男 | Director | 47 | 23.41万美元 | 未持股 | 2017-04-25 |
| Tassos Gianakakos. | 男 | President, Chief Executive Officer and Director | 44 | 110.50万美元 | 未持股 | 2017-04-25 |
| Kimberly Popovits | 女 | Director | 58 | 未披露 | 未持股 | 2017-04-25 |
| Wendy Yarno | 女 | Director | 62 | 未披露 | 未持股 | 2017-04-25 |
| Mark L. Perry | 男 | Non-executive chairman | 61 | 15.11万美元 | 未持股 | 2017-04-25 |
| Mary B. Cranston | 女 | Director | 69 | 28.98万美元 | 未持股 | 2017-04-25 |
| David P. Meeker | 男 | Director | 62 | 未披露 | 未持股 | 2017-04-25 |
| Eric J. Topol | 男 | Director | 62 | 14.46万美元 | 未持股 | 2017-04-25 |
| Kevin P. Starr | 男 | Director | 54 | 13.40万美元 | 未持股 | 2017-04-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tassos Gianakakos. | 男 | President, Chief Executive Officer and Director | 44 | 110.50万美元 | 未持股 | 2017-04-25 |
| Jake Bauer | 男 | Senior Vice President, Finance and Corporate Development | 38 | 60.27万美元 | 未持股 | 2017-04-25 |
| Joseph Lambing | 男 | Senior Vice President, Nonclinical and Pharmaceutical Development | 54 | 52.45万美元 | 未持股 | 2017-04-25 |
| Robert S. McDowell | 男 | Senior Vice President of Drug Discovery | 59 | 49.50万美元 | 未持股 | 2017-04-25 |
| Marc Semigran | 男 | Chief Medical Officer | 60 | 204.48万美元 | 未持股 | 2017-04-25 |
| June Lee | 女 | Chief Operating Officer | 51 | 未披露 | 未持股 | 2017-04-25 |
董事简历
中英对照 | 中文 | 英文- Sunil Agarwal
-
Sunil Agarwal自2014年8月起担任公司首席医疗官和高级副总裁。在加入Ultragenyx之前，他在Genentech工作了11年，担任不同的领导职位。目前，他担任高级副总裁的职位，2013年1月担任全眼科、代谢、神经科学、免疫学和传染病的临床开发全球负责人。在那之前，他担任免疫学与传染病的高级副总裁，2009年1月-2009年7月担任基因药物安全副总裁。2003年9月-2009年1月，他在Genentech的免疫学临床组织担任责任日益重大的职位，并且参与到多分子包括Raptiva，Rituxan和ocrelizumab的开发监督。他拥有康奈尔大学（Cornell University）神经生物学学士学位，后来获得了塔夫斯大学医学院（Tufts University School of Medicine）医学学士学位。他获得了华盛顿特区（Washington, D.C）国家儿童医疗中心（Children’s National Medical Center （CNMC））的居住权，随后加入乔治华盛顿大学医学院（George Washington University School of Medicine）担任儿科的助理临床教授。他在国家儿童医疗中心（CNMC）儿科急诊科工作。
Sunil Agarwal is a co-founder of Sana and has served as our Executive Vice President and Head of Development and Chief Medical Officer since July 2018. Dr. Agarwal is responsible for the overall strategy and execution of our pipeline, building Sana's development capabilities and helping to define and execute the overall corporate strategy. Prior to Sana, Dr. Agarwal was the President of Research and Development at Juno from April 2017 to May 2018 where he was responsible for the overall research and development strategy and execution. Prior to Juno, Dr. Agarwal served as partner at Sofinnova Ventures from August 2016 to April 2017. Dr. Agarwal also worked as the Chief Medical Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., a public biopharmaceutical company, from July 2014 to August 2016 where he was responsible for managing the company's clinical development and operations, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology, and toxicology functions. Dr. Agarwal also served in various leadership roles at Genentech, Inc. acquired by Roche Holdings, Inc. from 2003 to 2014 including Senior Vice President and Global Head of Clinical Development for ophthalmology, metabolism, neurosciences, immunology, and infectious diseases. Dr. Agarwal currently serves on the board of directors for Calithera Biosciences, Inc., a public biotechnology company, and previously served on the board of MyoKardia, Inc., a public biopharmaceutical company. Dr. Agarwal completed his residency at Children's National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department. He obtained a B.S. in neurobiology from Cornell University and an M.D. from Tufts University School of Medicine. - Sunil Agarwal自2014年8月起担任公司首席医疗官和高级副总裁。在加入Ultragenyx之前，他在Genentech工作了11年，担任不同的领导职位。目前，他担任高级副总裁的职位，2013年1月担任全眼科、代谢、神经科学、免疫学和传染病的临床开发全球负责人。在那之前，他担任免疫学与传染病的高级副总裁，2009年1月-2009年7月担任基因药物安全副总裁。2003年9月-2009年1月，他在Genentech的免疫学临床组织担任责任日益重大的职位，并且参与到多分子包括Raptiva，Rituxan和ocrelizumab的开发监督。他拥有康奈尔大学（Cornell University）神经生物学学士学位，后来获得了塔夫斯大学医学院（Tufts University School of Medicine）医学学士学位。他获得了华盛顿特区（Washington, D.C）国家儿童医疗中心（Children’s National Medical Center （CNMC））的居住权，随后加入乔治华盛顿大学医学院（George Washington University School of Medicine）担任儿科的助理临床教授。他在国家儿童医疗中心（CNMC）儿科急诊科工作。
- Sunil Agarwal is a co-founder of Sana and has served as our Executive Vice President and Head of Development and Chief Medical Officer since July 2018. Dr. Agarwal is responsible for the overall strategy and execution of our pipeline, building Sana's development capabilities and helping to define and execute the overall corporate strategy. Prior to Sana, Dr. Agarwal was the President of Research and Development at Juno from April 2017 to May 2018 where he was responsible for the overall research and development strategy and execution. Prior to Juno, Dr. Agarwal served as partner at Sofinnova Ventures from August 2016 to April 2017. Dr. Agarwal also worked as the Chief Medical Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., a public biopharmaceutical company, from July 2014 to August 2016 where he was responsible for managing the company's clinical development and operations, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology, and toxicology functions. Dr. Agarwal also served in various leadership roles at Genentech, Inc. acquired by Roche Holdings, Inc. from 2003 to 2014 including Senior Vice President and Global Head of Clinical Development for ophthalmology, metabolism, neurosciences, immunology, and infectious diseases. Dr. Agarwal currently serves on the board of directors for Calithera Biosciences, Inc., a public biotechnology company, and previously served on the board of MyoKardia, Inc., a public biopharmaceutical company. Dr. Agarwal completed his residency at Children's National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department. He obtained a B.S. in neurobiology from Cornell University and an M.D. from Tufts University School of Medicine.
- Tassos Gianakakos.
-
Tassos Gianakakos。2013年10月起担任本公司首席执行官和总裁；2013年10月起担任本公司董事会成员。此前，他曾于2006年9月-2013年3月被Allergan PLC收购前，担任MAP Pharmaceuticals, Inc.的高级副总裁和首席商务官；Gianakakos先生在推动公司的两大三期临床方案和LEVADEX监管机构备案中发挥了不可或缺的作用，以及成功地领导了与Allergan项目的共同促进合伙关系协议，以及与AstraZeneca PLC的关于该公司Unit Dose Budesonide项目的全球合伙关系。此前，他曾于2001年领导Codexis, Inc.（Maxygen, Inc.的分公司）的成立。在Codexis，他曾担任总裁、业务发展高级副总裁以及Codexis医药业务部全球主管。此前，他曾在Maxygen担任业务发展主管，领导该公司疫苗和生物工业平台的业务发展，以及融资活动，包括该公司的首次公开发行。此前，他曾在Merck & Co., Inc.疫苗部担任工艺工程师。他持有麻省理工学院（Massachusetts Institute of Technology）的化学工程和经济学学士学位，Northwestern大学的生物技术硕士学位和Harvard商学院的工商管理硕士学位。
Tassos Gianakakos. has served as our Chief Executive Officer and President since October 2013 and has been a member of our Board of Directors since October 2013. Prior to joining us, Mr. Gianakakos was senior vice president and chief business officer at MAP Pharmaceuticals, Inc., a biopharmaceutical company, from September 2006 to March 2013 when it was acquired by Allergan PLC. Prior to MAP Pharmaceuticals, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis’ Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, a biocatalyst development company, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co., Inc.’s vaccine division. Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School. - Tassos Gianakakos。2013年10月起担任本公司首席执行官和总裁；2013年10月起担任本公司董事会成员。此前，他曾于2006年9月-2013年3月被Allergan PLC收购前，担任MAP Pharmaceuticals, Inc.的高级副总裁和首席商务官；Gianakakos先生在推动公司的两大三期临床方案和LEVADEX监管机构备案中发挥了不可或缺的作用，以及成功地领导了与Allergan项目的共同促进合伙关系协议，以及与AstraZeneca PLC的关于该公司Unit Dose Budesonide项目的全球合伙关系。此前，他曾于2001年领导Codexis, Inc.（Maxygen, Inc.的分公司）的成立。在Codexis，他曾担任总裁、业务发展高级副总裁以及Codexis医药业务部全球主管。此前，他曾在Maxygen担任业务发展主管，领导该公司疫苗和生物工业平台的业务发展，以及融资活动，包括该公司的首次公开发行。此前，他曾在Merck & Co., Inc.疫苗部担任工艺工程师。他持有麻省理工学院（Massachusetts Institute of Technology）的化学工程和经济学学士学位，Northwestern大学的生物技术硕士学位和Harvard商学院的工商管理硕士学位。
- Tassos Gianakakos. has served as our Chief Executive Officer and President since October 2013 and has been a member of our Board of Directors since October 2013. Prior to joining us, Mr. Gianakakos was senior vice president and chief business officer at MAP Pharmaceuticals, Inc., a biopharmaceutical company, from September 2006 to March 2013 when it was acquired by Allergan PLC. Prior to MAP Pharmaceuticals, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis’ Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, a biocatalyst development company, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co., Inc.’s vaccine division. Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.
- Kimberly Popovits
-
Kimberly Popovits自2017年3月以来一直担任我们的董事会成员。Popovits女士自2009年1月起担任梦百合公司GenomicHealth，Inc.的总裁兼首席执行官，自2012年3月1日起担任董事会主席。在此之前，Popovits女士从2002年2月到2009年1月担任总裁兼首席运营官。1987年11月至2002年2月，Popovits女士在生物技术公司Genentech，Inc.担任过各种职务，最近的职务是2001年2月至2002年2月担任高级副总裁，市场营销与销售，1994年10月至2001年2月担任销售Vice President。在加入Genentech之前，Popovits女士曾担任American Critical Care东南地区的部门经理，该公司是美国医院供应公司的一个部门，是一家向医院提供梦百合产品的供应商。Popovits女士拥有密歇根州立大学（Michigan State University）商业学士学位。
Kimberly Popovits has served as a member of our Board of Directors since March 2017. Ms. Popovits has served as President and Chief Executive Officer of Genomic Health, Inc., a healthcare company, since January 2009 and as Chairman of the Board since March 1 2012. Prior to that, Ms. Popovits served as President and Chief Operating Officer from February 2002 to January 2009. From November 1987 to February 2002 Ms. Popovits served in various roles at Genentech, Inc., a biotechnology company, most recently serving as Senior Vice President, Marketing and Sales from February 2001 to February 2002 and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech, Ms. Popovits served as Division Manager, Southeast Region, for American Critical Care, a Division of American Hospital Supply, a supplier of healthcare products to hospitals. Ms. Popovits holds a B.A. in Business from Michigan State University. - Kimberly Popovits自2017年3月以来一直担任我们的董事会成员。Popovits女士自2009年1月起担任梦百合公司GenomicHealth，Inc.的总裁兼首席执行官，自2012年3月1日起担任董事会主席。在此之前，Popovits女士从2002年2月到2009年1月担任总裁兼首席运营官。1987年11月至2002年2月，Popovits女士在生物技术公司Genentech，Inc.担任过各种职务，最近的职务是2001年2月至2002年2月担任高级副总裁，市场营销与销售，1994年10月至2001年2月担任销售Vice President。在加入Genentech之前，Popovits女士曾担任American Critical Care东南地区的部门经理，该公司是美国医院供应公司的一个部门，是一家向医院提供梦百合产品的供应商。Popovits女士拥有密歇根州立大学（Michigan State University）商业学士学位。
- Kimberly Popovits has served as a member of our Board of Directors since March 2017. Ms. Popovits has served as President and Chief Executive Officer of Genomic Health, Inc., a healthcare company, since January 2009 and as Chairman of the Board since March 1 2012. Prior to that, Ms. Popovits served as President and Chief Operating Officer from February 2002 to January 2009. From November 1987 to February 2002 Ms. Popovits served in various roles at Genentech, Inc., a biotechnology company, most recently serving as Senior Vice President, Marketing and Sales from February 2001 to February 2002 and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech, Ms. Popovits served as Division Manager, Southeast Region, for American Critical Care, a Division of American Hospital Supply, a supplier of healthcare products to hospitals. Ms. Popovits holds a B.A. in Business from Michigan State University.
- Wendy Yarno
-
Wendy Yarno自2017年3月以来一直担任我们的董事会成员。Yarno女士于2008年9月从默克制药公司（一家制药公司）退休，此前在该公司担任了26年的商业和人力资源职位，资历越来越高，最近一次是在退休前担任首席营销官。在该职位上，Yarno女士领导了一个全球性组织，负责支持20多个治疗领域的药品上市前后商业化的所有方面。此前，她曾担任心血管/代谢美国业务部门总经理，以及高级副总裁，人力资源。从默克退休后，2010年9月至2011年9月，Yarno女士兼职担任Hemoshear LLC的首席营销官，该公司是一家生物技术研究公司，也是发现和评估新药化合物的基于人类细胞的代理系统的领先开发商。Yarno女士自2013年10月起担任Aratana Therapeutics（一家为宠物开发药物的生物制药公司）的董事会非执行主席。自2002年起，她还曾担任《财富》500强医疗器械公司圣犹达医疗公司的董事，直至2017年1月圣犹达医疗被雅培公司收购，她还曾担任专注于肿瘤产品的生物技术公司Medivation，Inc.的董事，从2013年4月到2016年9月Medivation被辉瑞公司收购；从2014年8月到2014年11月Durata Therapeutics（一家制药公司）被Actavis W.C.Holding Inc.收购。她也有过去担任几个小型私人公司董事会董事的经验。Yarno女士拥有波特兰州立大学（Portland State University）工商管理学士学位和坦普尔大学（Temple University）工商管理硕士学位。
Wendy Yarno has served as a member of our Board of Directors since March 2017. Ms. Yarno retired in September 2008 from Merck & Co., Inc., a pharmaceutical company, following a 26-year career there in commercial and human resource positions of increasing seniority, most recently Chief Marketing Officer before she retired. In that role, Ms. Yarno led a global organization charged with all aspects of supporting pre- and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. Prior to this role, she served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, and as Senior Vice President, Human Resources. After retiring from Merck, Ms. Yarno worked part-time as the Chief Marketing Officer of HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, from September 2010 through September 2011. Ms. Yarno has served as the non-executive Chairman of the Board of Aratana Therapeutics, a biopharmaceutical company developing medicines for pets, since October 2013. She also served as a director of St. Jude Medical, Inc., a Fortune 500 medical device company, since 2002 until January 2017 when St. Jude Medical was acquired by Abbott Laboratories; and of Medivation, Inc., a biotechnology company focused on oncology products, from April 2013 until September 2016 when Medivation was acquired by Pfizer; and of Durata Therapeutics, a pharmaceutical company, from August 2014 through November 2014 when it was acquired by Actavis W.C. Holding Inc. She also has past experience as a director for several small private company boards. Ms. Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A from Temple University. - Wendy Yarno自2017年3月以来一直担任我们的董事会成员。Yarno女士于2008年9月从默克制药公司（一家制药公司）退休，此前在该公司担任了26年的商业和人力资源职位，资历越来越高，最近一次是在退休前担任首席营销官。在该职位上，Yarno女士领导了一个全球性组织，负责支持20多个治疗领域的药品上市前后商业化的所有方面。此前，她曾担任心血管/代谢美国业务部门总经理，以及高级副总裁，人力资源。从默克退休后，2010年9月至2011年9月，Yarno女士兼职担任Hemoshear LLC的首席营销官，该公司是一家生物技术研究公司，也是发现和评估新药化合物的基于人类细胞的代理系统的领先开发商。Yarno女士自2013年10月起担任Aratana Therapeutics（一家为宠物开发药物的生物制药公司）的董事会非执行主席。自2002年起，她还曾担任《财富》500强医疗器械公司圣犹达医疗公司的董事，直至2017年1月圣犹达医疗被雅培公司收购，她还曾担任专注于肿瘤产品的生物技术公司Medivation，Inc.的董事，从2013年4月到2016年9月Medivation被辉瑞公司收购；从2014年8月到2014年11月Durata Therapeutics（一家制药公司）被Actavis W.C.Holding Inc.收购。她也有过去担任几个小型私人公司董事会董事的经验。Yarno女士拥有波特兰州立大学（Portland State University）工商管理学士学位和坦普尔大学（Temple University）工商管理硕士学位。
- Wendy Yarno has served as a member of our Board of Directors since March 2017. Ms. Yarno retired in September 2008 from Merck & Co., Inc., a pharmaceutical company, following a 26-year career there in commercial and human resource positions of increasing seniority, most recently Chief Marketing Officer before she retired. In that role, Ms. Yarno led a global organization charged with all aspects of supporting pre- and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. Prior to this role, she served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, and as Senior Vice President, Human Resources. After retiring from Merck, Ms. Yarno worked part-time as the Chief Marketing Officer of HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, from September 2010 through September 2011. Ms. Yarno has served as the non-executive Chairman of the Board of Aratana Therapeutics, a biopharmaceutical company developing medicines for pets, since October 2013. She also served as a director of St. Jude Medical, Inc., a Fortune 500 medical device company, since 2002 until January 2017 when St. Jude Medical was acquired by Abbott Laboratories; and of Medivation, Inc., a biotechnology company focused on oncology products, from April 2013 until September 2016 when Medivation was acquired by Pfizer; and of Durata Therapeutics, a pharmaceutical company, from August 2014 through November 2014 when it was acquired by Actavis W.C. Holding Inc. She also has past experience as a director for several small private company boards. Ms. Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A from Temple University.
- Mark L. Perry
-
Mark L. Perry，家驻三岩风险投资公司（一家风险资本公司）企业家。他也是途经治疗的董事长和MyoKardia 公司（两者都是私营生物技术公司）董事会成员，并且担任多个生物技术公司以及高科技公司独立董事。从2007年到2011年，他担任Aerovance 公司（一家生物制药公司）总裁、首席执行官和董事。加入Aerovance 之前，他担任吉利德科学公司（一家生物制药公司）高级商业顾问；从1994年到2004年他担任吉利德科学公司执行官，并担任多个职位，包括总法律顾问、首席财务官和最近才上任的运营部执行副总裁。从1981年到1994年，他在旧金山和加利福尼亚州帕洛阿尔托库利律师事务工作，并于1987年到1994年担任律师事务所合伙人。从2003年到2009年，他担任 Nuvelo有限公司董事。他持有伯克利加利福尼亚大学历史学学士学位以及达维斯加利福尼大学法律博士学位。
Mark L. Perry,serves on the boards of, and consults for, various companies and non-profit organizations. From 2012 to 2015, Mr. Perry served as an Entrepreneur-in-Residence at Third Rock Ventures, a venture capital firm. He served from 2007 to 2011 as president and chief executive officer of Aerovance, Inc., a biopharmaceutical company. He was an executive officer from 1994 to 2004 at Gilead Sciences, Inc., a biopharmaceutical company, serving in a variety of capacities, including general counsel, chief financial officer, and executive vice president of operations, responsible for worldwide sales and marketing, legal, manufacturing and facilities; he was also its senior business advisor until 2007. From 1981 to 1994, Mr. Perry was with the law firm Cooley LLP, where he was a partner for seven years. He served on the board of MyoKardia, Inc. from 2012 to 2020 and on the board of Global Blood Therapeutics, Inc. from 2015 to 2022. Mr. Perry holds a BA degree in History from the University of California, Berkeley, and a JD degree from the University of California, Davis. - Mark L. Perry，家驻三岩风险投资公司（一家风险资本公司）企业家。他也是途经治疗的董事长和MyoKardia 公司（两者都是私营生物技术公司）董事会成员，并且担任多个生物技术公司以及高科技公司独立董事。从2007年到2011年，他担任Aerovance 公司（一家生物制药公司）总裁、首席执行官和董事。加入Aerovance 之前，他担任吉利德科学公司（一家生物制药公司）高级商业顾问；从1994年到2004年他担任吉利德科学公司执行官，并担任多个职位，包括总法律顾问、首席财务官和最近才上任的运营部执行副总裁。从1981年到1994年，他在旧金山和加利福尼亚州帕洛阿尔托库利律师事务工作，并于1987年到1994年担任律师事务所合伙人。从2003年到2009年，他担任 Nuvelo有限公司董事。他持有伯克利加利福尼亚大学历史学学士学位以及达维斯加利福尼大学法律博士学位。
- Mark L. Perry,serves on the boards of, and consults for, various companies and non-profit organizations. From 2012 to 2015, Mr. Perry served as an Entrepreneur-in-Residence at Third Rock Ventures, a venture capital firm. He served from 2007 to 2011 as president and chief executive officer of Aerovance, Inc., a biopharmaceutical company. He was an executive officer from 1994 to 2004 at Gilead Sciences, Inc., a biopharmaceutical company, serving in a variety of capacities, including general counsel, chief financial officer, and executive vice president of operations, responsible for worldwide sales and marketing, legal, manufacturing and facilities; he was also its senior business advisor until 2007. From 1981 to 1994, Mr. Perry was with the law firm Cooley LLP, where he was a partner for seven years. He served on the board of MyoKardia, Inc. from 2012 to 2020 and on the board of Global Blood Therapeutics, Inc. from 2015 to 2022. Mr. Perry holds a BA degree in History from the University of California, Berkeley, and a JD degree from the University of California, Davis.
- Mary B. Cranston
-
Mary B. Cranston是国际律师事务所Pillsbury Winthrop Shaw Pittman LLP的高级合伙人（现已退休）。她从1999年1月到2006年4月是Pillsbury的主席和首席执行官，继续担任公司主席（直到2006年12月）。她是公司高级合伙人（直到2012年1月）。她也是International Rectifier Corporation和Juniper Networks, Inc.的董事，先前是Exponent, Inc.和GrafTech International, Inc.董事会成员（直到2014年5月）。她持有斯坦福大学（Stanford University）政治科学学士学位，斯坦福大学法学院（Stanford Law School）法学博士学位，洛杉矶加州大学（University of California）的教育心理学硕士学位。
Mary B. Cranston,current The Chemours Company; McAfee Corp.; Visa Inc..(prior) MyoKardia, Inc.; Exponent, Inc.; GrafTech International, Inc.; International Rectifier Corporation; Juniper Networks, Inc..Retired Senior Partner of Pillsbury Winthrop Shaw Pittman LLP, an international law firm.Chair and Chief Executive Officer of Pillsbury from January 1999 to April 2006; continued to serve as Chair of the firm until December 2006; Firm Senior Partner until January 2012.A.B. degree in Political Science from Stanford University, a J.D. degree from Stanford Law School and an M.A. degree in Educational Psychology from the University of California, Los Angeles. - Mary B. Cranston是国际律师事务所Pillsbury Winthrop Shaw Pittman LLP的高级合伙人（现已退休）。她从1999年1月到2006年4月是Pillsbury的主席和首席执行官，继续担任公司主席（直到2006年12月）。她是公司高级合伙人（直到2012年1月）。她也是International Rectifier Corporation和Juniper Networks, Inc.的董事，先前是Exponent, Inc.和GrafTech International, Inc.董事会成员（直到2014年5月）。她持有斯坦福大学（Stanford University）政治科学学士学位，斯坦福大学法学院（Stanford Law School）法学博士学位，洛杉矶加州大学（University of California）的教育心理学硕士学位。
- Mary B. Cranston,current The Chemours Company; McAfee Corp.; Visa Inc..(prior) MyoKardia, Inc.; Exponent, Inc.; GrafTech International, Inc.; International Rectifier Corporation; Juniper Networks, Inc..Retired Senior Partner of Pillsbury Winthrop Shaw Pittman LLP, an international law firm.Chair and Chief Executive Officer of Pillsbury from January 1999 to April 2006; continued to serve as Chair of the firm until December 2006; Firm Senior Partner until January 2012.A.B. degree in Political Science from Stanford University, a J.D. degree from Stanford Law School and an M.A. degree in Educational Psychology from the University of California, Los Angeles.
- David P. Meeker
-
David P. Meeker ，他是医学博士。他曾一直担任执行副总裁（2008年5月以来）、首席运营官（2010年4月以来），负责我们的个性化基因健康和生物外科业务，以及我们的公司制造业务。从2008年5月到2009年3月，他负责我们的移植业务。从2003年3月到2008年5月，他曾担任公司的高级副总裁兼总裁，负责迷幻药治疗。他于1994年加入Genzyme公司，也曾担任医疗事务副总裁（1996年10月至1998年6月）、负责医疗事务的高级副总裁（从1998年6月到2000年5月）、Genzyme公司的欧洲高级副总裁（从2000年5月到2003年3月）。加入Genzyme公司之前，他曾担任克里夫兰医疗中心（the Cleveland Clinic）的the Pulmonary Critical Care Fellowship的董事。他也曾担任Ohio State University的医学助理教授。
David P. Meeker has served as a member of our board of directors since November 2015 and became chairman of the board in April 2017. Dr. Meeker has served as President and Chief Executive officer of Genzyme, a unit of Sanofi, a global biotechnology company, since October 2011. Dr. Meeker oversees the company's two business units-Rare Diseases and Multiple Sclerosis. As an Executive Vice President of Sanofi, he is a member of Sanofi's Executive Committee. Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to Genzyme's merger with Sanofi in 2011 Dr. Meeker was Genzyme's Chief Operating Officer, responsible for its commercial organization, overseeing its business units, country management organization and global market access functions. He played an important role in the integration with Sanofi. Prior to joining Genzyme, Dr. Meeker was the director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Dr. Meeker is currently a member of the board of directors of MyoKardia, Inc. He has authored more than 40 articles and multiple book chapters. Dr. Meeker received his M.D. from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000. - David P. Meeker ，他是医学博士。他曾一直担任执行副总裁（2008年5月以来）、首席运营官（2010年4月以来），负责我们的个性化基因健康和生物外科业务，以及我们的公司制造业务。从2008年5月到2009年3月，他负责我们的移植业务。从2003年3月到2008年5月，他曾担任公司的高级副总裁兼总裁，负责迷幻药治疗。他于1994年加入Genzyme公司，也曾担任医疗事务副总裁（1996年10月至1998年6月）、负责医疗事务的高级副总裁（从1998年6月到2000年5月）、Genzyme公司的欧洲高级副总裁（从2000年5月到2003年3月）。加入Genzyme公司之前，他曾担任克里夫兰医疗中心（the Cleveland Clinic）的the Pulmonary Critical Care Fellowship的董事。他也曾担任Ohio State University的医学助理教授。
- David P. Meeker has served as a member of our board of directors since November 2015 and became chairman of the board in April 2017. Dr. Meeker has served as President and Chief Executive officer of Genzyme, a unit of Sanofi, a global biotechnology company, since October 2011. Dr. Meeker oversees the company's two business units-Rare Diseases and Multiple Sclerosis. As an Executive Vice President of Sanofi, he is a member of Sanofi's Executive Committee. Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to Genzyme's merger with Sanofi in 2011 Dr. Meeker was Genzyme's Chief Operating Officer, responsible for its commercial organization, overseeing its business units, country management organization and global market access functions. He played an important role in the integration with Sanofi. Prior to joining Genzyme, Dr. Meeker was the director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Dr. Meeker is currently a member of the board of directors of MyoKardia, Inc. He has authored more than 40 articles and multiple book chapters. Dr. Meeker received his M.D. from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.
- Eric J. Topol
-
Eric J. Topol，2011年10月起，担任本公司董事。2007年1月起，他担任Scripps Translational Science Institute的主任，这是Clinical and Translational Science Award Consortium的项目，由National Institutes of Health资助。他目前是Scripps Research Institute的基因组学教授、Scripps Health的首席学术官、Scripps Clinic的高级心脏病学专家。加入Scripps之前，他是Case Western的遗传学教授；在Cleveland Clinic 主持了15年的心血管医学部；还创办了Cleveland Clinic Lerner College of Medicine。他曾担任Cardionet的科学顾问委员会成员；目前是无线医疗技术上市公司DexCom的董事。
Eric J. Topol,has served on Dexcom, Inc. Board since July 2009. Since January 2007, Dr. Topol has served as the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award Consortium. He is Executive Vice President and Professor of Molecular Medicine at the Scripps Research Institute, and a senior consulting cardiologist at Scripps Clinic. Prior to Scripps, Dr. Topol served on the faculty of Case Western Reserve University as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and founded the Cleveland Clinic Lerner College of Medicine. Dr. Topol serves as a digital medical advisor to Blue Cross Blue Shield Association. In April 2009, he co-founded the West Wireless Health Institute, a non-profit foundation for applied medical research and policy on the prevention of aging. As a practicing physician, academic and thought leader in wireless healthcare technologies, Dr. Topol is uniquely situated to provide the Board with guidance on its technology, clinical and market development. - Eric J. Topol，2011年10月起，担任本公司董事。2007年1月起，他担任Scripps Translational Science Institute的主任，这是Clinical and Translational Science Award Consortium的项目，由National Institutes of Health资助。他目前是Scripps Research Institute的基因组学教授、Scripps Health的首席学术官、Scripps Clinic的高级心脏病学专家。加入Scripps之前，他是Case Western的遗传学教授；在Cleveland Clinic 主持了15年的心血管医学部；还创办了Cleveland Clinic Lerner College of Medicine。他曾担任Cardionet的科学顾问委员会成员；目前是无线医疗技术上市公司DexCom的董事。
- Eric J. Topol,has served on Dexcom, Inc. Board since July 2009. Since January 2007, Dr. Topol has served as the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award Consortium. He is Executive Vice President and Professor of Molecular Medicine at the Scripps Research Institute, and a senior consulting cardiologist at Scripps Clinic. Prior to Scripps, Dr. Topol served on the faculty of Case Western Reserve University as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and founded the Cleveland Clinic Lerner College of Medicine. Dr. Topol serves as a digital medical advisor to Blue Cross Blue Shield Association. In April 2009, he co-founded the West Wireless Health Institute, a non-profit foundation for applied medical research and policy on the prevention of aging. As a practicing physician, academic and thought leader in wireless healthcare technologies, Dr. Topol is uniquely situated to provide the Board with guidance on its technology, clinical and market development.
- Kevin P. Starr
-
Kevin P. Starr。 ， 自2006年12月起担任公司董事。2007年4月他联合创立了 Third Rock Ventures（一家风险资本公司），并担任其合伙人。2003年1月到2007年3月他参加了生命科学和娱乐行业的多个创业活动。从2001年12月懂啊2002年12月担任Millennium首席运营官。他还从1998年12月到2002年12月担任Millennium首席财务官。现任Agios Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., PanOptica, Inc., MyoKardia, Inc., Global Blood Therapeutics, Inc., Afferent Pharmaceutical, Ember Therapeutics和SAGE Therapeutics董事。他持有Boston College企业金融理学硕士学位以及Colby College数学和商业学士学位。
Kevin P. Starr has served as a member of our Board of Directors since June 2012. In April 2007 Mr. Starr co-founded Third Rock Ventures, where he remains a partner. From January 2003 to March 2007 Mr. Starr undertook a number of entrepreneurial endeavors in the life science and entertainment industries. From December 2001 to December 2002 Mr. Starr served as chief operating officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company. He also served as Millennium Pharmaceuticals’ chief financial officer from December 1998 to December 2002. Mr. Starr currently serves on the board of directors of Sage Therapeutics, Inc., Decibel Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., and PanOptica, Inc., all biopharmaceutical companies. Mr. Starr received an M.S. in corporate finance from Boston College and a B.S./B.A. in mathematics and business from Colby College. - Kevin P. Starr。 ， 自2006年12月起担任公司董事。2007年4月他联合创立了 Third Rock Ventures（一家风险资本公司），并担任其合伙人。2003年1月到2007年3月他参加了生命科学和娱乐行业的多个创业活动。从2001年12月懂啊2002年12月担任Millennium首席运营官。他还从1998年12月到2002年12月担任Millennium首席财务官。现任Agios Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., PanOptica, Inc., MyoKardia, Inc., Global Blood Therapeutics, Inc., Afferent Pharmaceutical, Ember Therapeutics和SAGE Therapeutics董事。他持有Boston College企业金融理学硕士学位以及Colby College数学和商业学士学位。
- Kevin P. Starr has served as a member of our Board of Directors since June 2012. In April 2007 Mr. Starr co-founded Third Rock Ventures, where he remains a partner. From January 2003 to March 2007 Mr. Starr undertook a number of entrepreneurial endeavors in the life science and entertainment industries. From December 2001 to December 2002 Mr. Starr served as chief operating officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company. He also served as Millennium Pharmaceuticals’ chief financial officer from December 1998 to December 2002. Mr. Starr currently serves on the board of directors of Sage Therapeutics, Inc., Decibel Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., and PanOptica, Inc., all biopharmaceutical companies. Mr. Starr received an M.S. in corporate finance from Boston College and a B.S./B.A. in mathematics and business from Colby College.
高管简历
中英对照 | 中文 | 英文- Tassos Gianakakos.
Tassos Gianakakos。2013年10月起担任本公司首席执行官和总裁；2013年10月起担任本公司董事会成员。此前，他曾于2006年9月-2013年3月被Allergan PLC收购前，担任MAP Pharmaceuticals, Inc.的高级副总裁和首席商务官；Gianakakos先生在推动公司的两大三期临床方案和LEVADEX监管机构备案中发挥了不可或缺的作用，以及成功地领导了与Allergan项目的共同促进合伙关系协议，以及与AstraZeneca PLC的关于该公司Unit Dose Budesonide项目的全球合伙关系。此前，他曾于2001年领导Codexis, Inc.（Maxygen, Inc.的分公司）的成立。在Codexis，他曾担任总裁、业务发展高级副总裁以及Codexis医药业务部全球主管。此前，他曾在Maxygen担任业务发展主管，领导该公司疫苗和生物工业平台的业务发展，以及融资活动，包括该公司的首次公开发行。此前，他曾在Merck & Co., Inc.疫苗部担任工艺工程师。他持有麻省理工学院（Massachusetts Institute of Technology）的化学工程和经济学学士学位，Northwestern大学的生物技术硕士学位和Harvard商学院的工商管理硕士学位。
Tassos Gianakakos. has served as our Chief Executive Officer and President since October 2013 and has been a member of our Board of Directors since October 2013. Prior to joining us, Mr. Gianakakos was senior vice president and chief business officer at MAP Pharmaceuticals, Inc., a biopharmaceutical company, from September 2006 to March 2013 when it was acquired by Allergan PLC. Prior to MAP Pharmaceuticals, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis’ Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, a biocatalyst development company, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co., Inc.’s vaccine division. Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.- Tassos Gianakakos。2013年10月起担任本公司首席执行官和总裁；2013年10月起担任本公司董事会成员。此前，他曾于2006年9月-2013年3月被Allergan PLC收购前，担任MAP Pharmaceuticals, Inc.的高级副总裁和首席商务官；Gianakakos先生在推动公司的两大三期临床方案和LEVADEX监管机构备案中发挥了不可或缺的作用，以及成功地领导了与Allergan项目的共同促进合伙关系协议，以及与AstraZeneca PLC的关于该公司Unit Dose Budesonide项目的全球合伙关系。此前，他曾于2001年领导Codexis, Inc.（Maxygen, Inc.的分公司）的成立。在Codexis，他曾担任总裁、业务发展高级副总裁以及Codexis医药业务部全球主管。此前，他曾在Maxygen担任业务发展主管，领导该公司疫苗和生物工业平台的业务发展，以及融资活动，包括该公司的首次公开发行。此前，他曾在Merck & Co., Inc.疫苗部担任工艺工程师。他持有麻省理工学院（Massachusetts Institute of Technology）的化学工程和经济学学士学位，Northwestern大学的生物技术硕士学位和Harvard商学院的工商管理硕士学位。
- Tassos Gianakakos. has served as our Chief Executive Officer and President since October 2013 and has been a member of our Board of Directors since October 2013. Prior to joining us, Mr. Gianakakos was senior vice president and chief business officer at MAP Pharmaceuticals, Inc., a biopharmaceutical company, from September 2006 to March 2013 when it was acquired by Allergan PLC. Prior to MAP Pharmaceuticals, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis’ Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, a biocatalyst development company, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co., Inc.’s vaccine division. Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.
- Jake Bauer
Jake Bauer，2014年7月起担任本公司业务发展和商务运营副总裁。此前，他曾于2011年5月-2014年7月期间，在一家生物技术公司- Ablexis, LLC担任商务运营副总裁和企业发展主管。在Ablexis，他领导该公司的企业战略活动发展和实施，监管商务运营。此前，他曾于2007-2011年在Third Rock Ventures担任负责人，识别、评估和开发新的投资机会，协助初创企业、企业发展和投资组合公司的经营以及协商融资。在Third Rock Ventures，他积极参与各种顶尖生物医药公司的事务，包括Agios Pharmaceuticals, Inc.、CytomX Therapeutics Inc.、Global Blood Therapeutics, Inc.和Zafgen, Inc.。此前，他曾在Royalty Pharma AG的投资部门和Endo Pharmaceuticals Inc.的业务发展部门担任数个职位，此前曾在Putnam Associates担任管理顾问。他持有Duke大学的生物学学士学位和经济学学士学位，以及Harvard商学院的工商管理硕士学位。
Jake Bauer,serves on our board of directors. Prior to MyoKardia Inc.’s acquisition by Bristol Myers Squibb NYSE: BMY in November 2020 Mr. Bauer served as the Chief Business Officer of MyoKardia, Inc. since April 2018. Mr. Bauer has also served as the Senior Vice President, Finance and Corporate Development and Principal Financial Officer of MyoKardia, Inc. from July 2016 to April 2018 and as the Vice President, Business Development and Business Operations of MyoKardia, Inc. from July 2014 to July 2016. Mr. Bauer also serves on the board of directors of Phoenix Tissue Repair, Inc. since November 2018 and served as a director of ARYA Sciences Acquisition Corp II from July 2020 to October 2020. Prior to joining MyoKardia, Inc., Mr. Bauer has served as Vice President, Business Operations and head of corporate development at Ablexis, LLC (“Ablexis”), a biotechnology company, from May 2011 to July 2014. At Ablexis, he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations. Prior to Ablexis, Mr. Bauer has served as a principal at Third Rock Ventures from 2007 to 2011 where he identified, evaluated and developed new opportunities for investment, assisted with startup, corporate development and operations of portfolio companies, and negotiated financings. While at Third Rock Ventures, he was actively involved in a variety of leading biopharmaceutical companies including Agios Pharmaceuticals, Inc., CytomX Therapeutics Inc., and Global Blood Therapeutics, Inc. Prior to Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma AG and the business development group at Endo Pharmaceuticals Inc. and was previously a management consultant at Putnam Associates. Mr. Bauer holds a BS in biology and a BA in economics from Duke University and an MBA from Harvard Business School.- Jake Bauer，2014年7月起担任本公司业务发展和商务运营副总裁。此前，他曾于2011年5月-2014年7月期间，在一家生物技术公司- Ablexis, LLC担任商务运营副总裁和企业发展主管。在Ablexis，他领导该公司的企业战略活动发展和实施，监管商务运营。此前，他曾于2007-2011年在Third Rock Ventures担任负责人，识别、评估和开发新的投资机会，协助初创企业、企业发展和投资组合公司的经营以及协商融资。在Third Rock Ventures，他积极参与各种顶尖生物医药公司的事务，包括Agios Pharmaceuticals, Inc.、CytomX Therapeutics Inc.、Global Blood Therapeutics, Inc.和Zafgen, Inc.。此前，他曾在Royalty Pharma AG的投资部门和Endo Pharmaceuticals Inc.的业务发展部门担任数个职位，此前曾在Putnam Associates担任管理顾问。他持有Duke大学的生物学学士学位和经济学学士学位，以及Harvard商学院的工商管理硕士学位。
- Jake Bauer,serves on our board of directors. Prior to MyoKardia Inc.’s acquisition by Bristol Myers Squibb NYSE: BMY in November 2020 Mr. Bauer served as the Chief Business Officer of MyoKardia, Inc. since April 2018. Mr. Bauer has also served as the Senior Vice President, Finance and Corporate Development and Principal Financial Officer of MyoKardia, Inc. from July 2016 to April 2018 and as the Vice President, Business Development and Business Operations of MyoKardia, Inc. from July 2014 to July 2016. Mr. Bauer also serves on the board of directors of Phoenix Tissue Repair, Inc. since November 2018 and served as a director of ARYA Sciences Acquisition Corp II from July 2020 to October 2020. Prior to joining MyoKardia, Inc., Mr. Bauer has served as Vice President, Business Operations and head of corporate development at Ablexis, LLC (“Ablexis”), a biotechnology company, from May 2011 to July 2014. At Ablexis, he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations. Prior to Ablexis, Mr. Bauer has served as a principal at Third Rock Ventures from 2007 to 2011 where he identified, evaluated and developed new opportunities for investment, assisted with startup, corporate development and operations of portfolio companies, and negotiated financings. While at Third Rock Ventures, he was actively involved in a variety of leading biopharmaceutical companies including Agios Pharmaceuticals, Inc., CytomX Therapeutics Inc., and Global Blood Therapeutics, Inc. Prior to Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma AG and the business development group at Endo Pharmaceuticals Inc. and was previously a management consultant at Putnam Associates. Mr. Bauer holds a BS in biology and a BA in economics from Duke University and an MBA from Harvard Business School.
- Joseph Lambing
Joseph Lambing，2014年3月起担任Myokardia, Inc.非临床和医药发展高级副总裁。此前，2003年9月-2013年1月期间曾在Portola Pharmaceuticals, Inc.担任发展高级副总裁，在该公司创立以来监管所有的临床前和医药发展活动。此前，2002年2月-2003年11月，担任洛杉矶Millennium Pharmaceuticals, Inc.的药品安全和处置主管；1994年11月-2002年2月期间担任COR Therapeutics, Inc.的科学家，随后担任DMPK和毒理学主管。在他的职业生涯中，曾致力于十多个新化学实体的许多NDA和IND申请，以及致力于众多申请以支持各种其他国家临床试验。他持有Missouri大学的化学学士学位和生物化学博士学位，并且是圣地亚哥California大学的博士后。
Joseph Lambing has served as Myokardia, Inc. Senior Vice President, Nonclinical and Pharmaceutical Development since March 2014. Prior to joining Myokardia, Inc., he was senior vice president of development for Portola Pharmaceuticals, Inc., a biopharmaceutical company, where he oversaw all preclinical and pharmaceutical development activities since the company's founding from September 2003 to January 2013. Prior to Portola Pharmaceuticals, Dr. Lambing served as director of drug safety and disposition for Millennium Pharmaceuticals, Inc.'s, a biopharmaceutical company, San Francisco site from February 2002 to November 2003 and as a scientist and then director of DMPK and toxicology at COR Therapeutics, Inc. from November 1994 to February 2002. During his career, Dr. Lambing has contributed to numerous NDA and IND filings for more than a dozen new chemical entities, as well as numerous filings to support a variety of clinical trials in other countries. Dr. Lambing holds a B.S. in chemistry and a Ph.D. in biochemistry from the University of Missouri, and was a postdoctoral fellow at the University of California, San Diego.- Joseph Lambing，2014年3月起担任Myokardia, Inc.非临床和医药发展高级副总裁。此前，2003年9月-2013年1月期间曾在Portola Pharmaceuticals, Inc.担任发展高级副总裁，在该公司创立以来监管所有的临床前和医药发展活动。此前，2002年2月-2003年11月，担任洛杉矶Millennium Pharmaceuticals, Inc.的药品安全和处置主管；1994年11月-2002年2月期间担任COR Therapeutics, Inc.的科学家，随后担任DMPK和毒理学主管。在他的职业生涯中，曾致力于十多个新化学实体的许多NDA和IND申请，以及致力于众多申请以支持各种其他国家临床试验。他持有Missouri大学的化学学士学位和生物化学博士学位，并且是圣地亚哥California大学的博士后。
- Joseph Lambing has served as Myokardia, Inc. Senior Vice President, Nonclinical and Pharmaceutical Development since March 2014. Prior to joining Myokardia, Inc., he was senior vice president of development for Portola Pharmaceuticals, Inc., a biopharmaceutical company, where he oversaw all preclinical and pharmaceutical development activities since the company's founding from September 2003 to January 2013. Prior to Portola Pharmaceuticals, Dr. Lambing served as director of drug safety and disposition for Millennium Pharmaceuticals, Inc.'s, a biopharmaceutical company, San Francisco site from February 2002 to November 2003 and as a scientist and then director of DMPK and toxicology at COR Therapeutics, Inc. from November 1994 to February 2002. During his career, Dr. Lambing has contributed to numerous NDA and IND filings for more than a dozen new chemical entities, as well as numerous filings to support a variety of clinical trials in other countries. Dr. Lambing holds a B.S. in chemistry and a Ph.D. in biochemistry from the University of Missouri, and was a postdoctoral fellow at the University of California, San Diego.
- Robert S. McDowell
Robert S. McDowell，2012年7月起担任本公司药物发现高级副总裁。此前，2008年10月-2012年7月，他领导3-V Biosciences, Inc.的药物发现。此前，2000年1月-2008年，他在Sunesis Pharmaceuticals, Inc.担任研究副总裁，监管药物发现、转化型研究和制造职能部门。此前，他曾领导Axys Pharmaceuticals, Inc.的结构化学部门。此前，曾担任Genentech Inc.的高级科学家，开发了成功的肽设计战略。他曾发表了超过40篇同行评议的手稿，是一位拥有超过20项美国专利的发明家。他持有Butler大学的化学和物理学士学位，以及California大学Berkeley分校的化学博士学位。
Robert S. McDowell has served as our Senior Vice President of Drug Discovery since July 2012. Prior to joining us, Dr. McDowell led drug discovery at 3-V Biosciences, Inc. from October 2008 to July 2012 advancing the company’s lead program into development. Prior to 3-V Biosciences, he served as vice president of research at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, from January 2000 to 2008 where he oversaw drug discovery, translational research and manufacturing functions. Prior to Sunesis Pharmaceuticals, Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals, Inc. Before joining Axys, Dr. McDowell was a senior scientist at Genentech Inc., where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents. Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California, Berkeley.- Robert S. McDowell，2012年7月起担任本公司药物发现高级副总裁。此前，2008年10月-2012年7月，他领导3-V Biosciences, Inc.的药物发现。此前，2000年1月-2008年，他在Sunesis Pharmaceuticals, Inc.担任研究副总裁，监管药物发现、转化型研究和制造职能部门。此前，他曾领导Axys Pharmaceuticals, Inc.的结构化学部门。此前，曾担任Genentech Inc.的高级科学家，开发了成功的肽设计战略。他曾发表了超过40篇同行评议的手稿，是一位拥有超过20项美国专利的发明家。他持有Butler大学的化学和物理学士学位，以及California大学Berkeley分校的化学博士学位。
- Robert S. McDowell has served as our Senior Vice President of Drug Discovery since July 2012. Prior to joining us, Dr. McDowell led drug discovery at 3-V Biosciences, Inc. from October 2008 to July 2012 advancing the company’s lead program into development. Prior to 3-V Biosciences, he served as vice president of research at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, from January 2000 to 2008 where he oversaw drug discovery, translational research and manufacturing functions. Prior to Sunesis Pharmaceuticals, Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals, Inc. Before joining Axys, Dr. McDowell was a senior scientist at Genentech Inc., where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents. Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California, Berkeley.
- Marc Semigran
Marc Semigran自2016年12月起担任我们的首席医疗官。他曾担任the Massachusetts General Hospital Heart Fault and Cardiac Transplant Program的医学董事（从2004年4月到2016年11月），在那里他负责心力衰竭患者护理的总体方向，包括那些需要或已经接受心脏移植的患者。Semigran博士还从2010年1月至今担任哈佛医学院（Harvard Medical School）的医学副教授。他是the Harvard/MIT Health Sciences and Technology Program的毕业生，并在Massachusetts General Hospital完成内科住院医师和心脏病学研究金培训。Semigran博士拥有哈佛医学院（Harvard Medical School）的医学博士学位，并持有哈佛大学（Harvard University）化学AB和AM学位。
Marc Semigran will serve as a director following the completion of this offering. In June 2021 Dr. Semigran was appointed as chief medical officer of Renovacor, Inc., an early-stage biotechnology company focused on the development of therapies for cardiovascular and central nervous system diseases. Prior to joining Renovacor, Dr. Semigran was an Associate Professor of Medicine at Harvard Medical School, a position he held from January 2010-February 2017. He previously served as Chief Medical Officer of MyoKardia from December 2016 until the acquisition of MyoKardia by Bristol-Myers Squibb in 2020 for approximately $13.1 billion. Prior to MyoKardia, from April 2004 through February 2017 Dr. Semigran served as Medical Director of the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program, where he was responsible for leading the overall direction of the care of heart failure patients, including with respect to cardiac transplantation. He is an active investigator in translational and clinical medicine as applied to heart failure and cardiomyopathy. His research was funded by NIH and other peer-reviewed grants, and continues with industry funding. Dr Semigran is a graduate of the Harvard/MIT Health Sciences and Technology Program and completed his internal medicine residency and cardiology fellowship training at Massachusetts General Hospital. Dr. Semigran holds an M.D. from Harvard Medical School and an AB/AM in chemistry from Harvard University.- Marc Semigran自2016年12月起担任我们的首席医疗官。他曾担任the Massachusetts General Hospital Heart Fault and Cardiac Transplant Program的医学董事（从2004年4月到2016年11月），在那里他负责心力衰竭患者护理的总体方向，包括那些需要或已经接受心脏移植的患者。Semigran博士还从2010年1月至今担任哈佛医学院（Harvard Medical School）的医学副教授。他是the Harvard/MIT Health Sciences and Technology Program的毕业生，并在Massachusetts General Hospital完成内科住院医师和心脏病学研究金培训。Semigran博士拥有哈佛医学院（Harvard Medical School）的医学博士学位，并持有哈佛大学（Harvard University）化学AB和AM学位。
- Marc Semigran will serve as a director following the completion of this offering. In June 2021 Dr. Semigran was appointed as chief medical officer of Renovacor, Inc., an early-stage biotechnology company focused on the development of therapies for cardiovascular and central nervous system diseases. Prior to joining Renovacor, Dr. Semigran was an Associate Professor of Medicine at Harvard Medical School, a position he held from January 2010-February 2017. He previously served as Chief Medical Officer of MyoKardia from December 2016 until the acquisition of MyoKardia by Bristol-Myers Squibb in 2020 for approximately $13.1 billion. Prior to MyoKardia, from April 2004 through February 2017 Dr. Semigran served as Medical Director of the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program, where he was responsible for leading the overall direction of the care of heart failure patients, including with respect to cardiac transplantation. He is an active investigator in translational and clinical medicine as applied to heart failure and cardiomyopathy. His research was funded by NIH and other peer-reviewed grants, and continues with industry funding. Dr Semigran is a graduate of the Harvard/MIT Health Sciences and Technology Program and completed his internal medicine residency and cardiology fellowship training at Massachusetts General Hospital. Dr. Semigran holds an M.D. from Harvard Medical School and an AB/AM in chemistry from Harvard University.
- June Lee
June Lee自2017年2月起担任我们的首席运营官。加入我们之前，她曾任职加州大学旧金山分校（the University of California，San Francisco“；UCSF”；）的教员（2011年4月以来），在那里她曾担任临床和转化科学研究所（the Clinical and Translational Science Institute）的催化剂项目主管，以及医学院教授，并负责在大学促进和支持翻译研究的整体战略和运营。Catalyst是用于治疗学，设备，诊断和数字健康技术的UCSF内部加速器。在加入UCSF之前，Lee博士从2006年到2011年担任Genentech，Inc.早期临床开发的疾病领域负责人，在那里她负责多个治疗领域的所有战略和活动以及早期临床开发小组的员工管理、预算和资源分配。2004年至2006年，李博士担任Genentech，Inc.临床开发小组的医学主任，负责该公司许可产品的临床活动。Lee博士拥有约翰霍普金斯大学（Johns Hopkins University）的化学学士学位和加州大学戴维斯分校（University of California，Davis）的医学博士学位。
June Lee,has been one of Abivax Sa independent directors since July 2023. Dr. Lee has served as a venture partner at 5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic Translation's Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific Advisory Board for Foresite Labs, and previously served as a member of the board of directors of CinCor Pharma, Inc. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis.- June Lee自2017年2月起担任我们的首席运营官。加入我们之前，她曾任职加州大学旧金山分校（the University of California，San Francisco“；UCSF”；）的教员（2011年4月以来），在那里她曾担任临床和转化科学研究所（the Clinical and Translational Science Institute）的催化剂项目主管，以及医学院教授，并负责在大学促进和支持翻译研究的整体战略和运营。Catalyst是用于治疗学，设备，诊断和数字健康技术的UCSF内部加速器。在加入UCSF之前，Lee博士从2006年到2011年担任Genentech，Inc.早期临床开发的疾病领域负责人，在那里她负责多个治疗领域的所有战略和活动以及早期临床开发小组的员工管理、预算和资源分配。2004年至2006年，李博士担任Genentech，Inc.临床开发小组的医学主任，负责该公司许可产品的临床活动。Lee博士拥有约翰霍普金斯大学（Johns Hopkins University）的化学学士学位和加州大学戴维斯分校（University of California，Davis）的医学博士学位。
- June Lee,has been one of Abivax Sa independent directors since July 2023. Dr. Lee has served as a venture partner at 5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic Translation's Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific Advisory Board for Foresite Labs, and previously served as a member of the board of directors of CinCor Pharma, Inc. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis.